Arvinas/$ARVN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Arvinas
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
Ticker
$ARVN
Sector
Primary listing
Employees
430
Headquarters
Website
Arvinas Metrics
BasicAdvanced
$706M
-
-$1.00
2.23
-
Price and volume
Market cap
$706M
Beta
2.23
52-week high
$27.57
52-week low
$5.90
Average daily volume
2M
Financial strength
Current ratio
5.637
Quick ratio
5.528
Long term debt to equity
1.329
Total debt to equity
1.625
Profitability
EBITDA (TTM)
-113.8
Gross margin (TTM)
57.40%
Net profit margin (TTM)
-19.47%
Operating margin (TTM)
-31.52%
Effective tax rate (TTM)
-0.14%
Revenue per employee (TTM)
$870,000
Management effectiveness
Return on assets (TTM)
-6.71%
Return on equity (TTM)
-12.00%
Valuation
Price to revenue (TTM)
1.868
Price to book
1.15
Price to tangible book (TTM)
1.15
Price to free cash flow (TTM)
-1.745
Free cash flow yield (TTM)
-57.31%
Free cash flow per share (TTM)
-5.507
Growth
Revenue change (TTM)
299.57%
Earnings per share change (TTM)
-79.97%
3-year revenue growth (CAGR)
53.64%
3-year earnings per share growth (CAGR)
-39.23%
What the Analysts think about Arvinas
Analyst ratings (Buy, Hold, Sell) for Arvinas stock.
Bulls say / Bears say
Vepdegestrant extended progression-free survival by five months in ESR1-mutant breast cancer patients compared to two months for AstraZeneca’s Faslodex, demonstrating clear clinical superiority. (Reuters)
As an oral PROTAC ER degrader, vepdegestrant offers the convenience advantage over intramuscular Faslodex, which may lead to better patient adherence and greater uptake. (Reuters)
Leerink Partners projects vepdegestrant could reach $576 million in peak annual sales by 2032, signaling strong revenue potential if approved. (Reuters)
Vepdegestrant did not achieve a statistically significant improvement in progression-free survival in the full intent-to-treat set, limiting its commercial reach beyond patients with specific biomarkers. (Reuters)
Arvinas shares dropped 37% in pre-market trade after releasing mixed Phase III results, highlighting investor doubts about the lead drug’s market outlook. (Reuters)
Arvinas is discontinuing two other planned late-stage vepdegestrant studies, shrinking its pipeline and raising execution risk for its prime PROTAC program. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 5 Sept 2025.
Arvinas Financial Performance
Revenues and expenses
Arvinas Earnings Performance
Company profitability
Arvinas News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Arvinas stock?
Arvinas (ARVN) has a market cap of $706M as of October 05, 2025.
What is the P/E ratio for Arvinas stock?
The price to earnings (P/E) ratio for Arvinas (ARVN) stock is 0 as of October 05, 2025.
Does Arvinas stock pay dividends?
No, Arvinas (ARVN) stock does not pay dividends to its shareholders as of October 05, 2025.
When is the next Arvinas dividend payment date?
Arvinas (ARVN) stock does not pay dividends to its shareholders.
What is the beta indicator for Arvinas?
Arvinas (ARVN) has a beta rating of 2.23. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.